Skip to main content

Table 3 Definition of FAP-related disease progression by patient stratum

From: Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial

Patient stratum Disease progression
Pre-colectomy • ≥25 % increase in polyp burden (number, size) from baseline
• Presence of large, sessile or ulcerated adenoma (not amenable to excision)
• High-grade dysplasia
• Large villous adenoma
• In-situ or invasive cancer
Retained rectum/ileal pouch polyposis • ≥25 % increase in polyp burden (number, size) from baseline
• Excisional intervention to remove any polyp ≥10 mm
• High-grade dysplasia in any polyp
• In-situ or invasive cancer on any biopsy
Duodenal polyposis • Increase in Spigelman Stage (2–4) from baseline
• Need for excisional intervention
• Development of cancer
• Death (endoscopy/intervention related)